Several clinical studies revealed that the combination of mAb ch14.18, IL-2 and GM-CSF or variant GD2 antibody fused to IL-2 (mAb hu14.18-IL2) showed increased efficiency to achieve long-term event-free survival of neuroblastoma patients [24, 25]. This evidence concerns the gene IL2 and neuroblastoma.